

## Physician Practice Variation in head and neck cancer therapy: results of a national survey

Cros Fanny<sup>(1)</sup>, Jr, Lamy Sébastien<sup>(2)</sup>, PhD, Grosclaude Pascale<sup>(3)</sup>, PhD, Nebout Antoine<sup>(4)</sup>, PhD, Chabrillac Emilien<sup>(5)</sup>, MD, Vergez Sébastien<sup>(5)</sup>, MD, PhD, Bories Pierre<sup>(6)</sup>, MD, PhD, Dupret-Bories Agnès<sup>(7)</sup>, MD, PhD

(1) Cros Fanny: ENT Resident

*Service d'ORL et de chirurgie cervico-faciale, CHU de Toulouse, hôpital Larrey, 24, chemin de Pouvoirville, TSA 30030, 31059, Toulouse cedex 9, France.*

(2) Lamy Sébastien: PhD

*Laboratoire d'épidémiologie et analyses en santé publique (LEASP) - UMR 1027, Inserm-Université Paul-Sabatier Toulouse III, Faculté de médecine, CHU Toulouse, Faculté de médecine de Purpan, 37, allée Jules-Guesde, 31073 Toulouse cedex, France.*

(3) Grosclaude Pascale: PhD

*Laboratoire d'épidémiologie et analyses en santé publique (LEASP) - UMR 1027, Inserm-Université Paul-Sabatier Toulouse III, Faculté de médecine, 37, allée Jules-Guesde, 31062 Toulouse cedex 9, France; CHU Toulouse, Faculté de médecine de Purpan, 37, allée Jules-Guesde, 31073 Toulouse cedex, France.*

(4) Nebout Antoine: PhD

*ALISS, UR1303, INRA, Ivry-Sur-Seine, 94205, France.*

(5) Vergez Sébastien: MD, PhD and Emilien Chabrillac, MD

*Service d'otorhinolaryngologie et chirurgie cervico-faciale, hôpital Toulouse-Rangueil-Larrey, 31059 Toulouse, France*

(6) Bories Pierre: MD, PhD

*Réseau Onco-occitanie, Institut Universitaire du Cancer de Toulouse-Oncopôle, avenue Hubert Curien, Toulouse, France.*

(7) Dupret-Bories Agnès, MD, PhD

*Service d'otorhinolaryngologie et chirurgie cervico-faciale, Institut Universitaire du Cancer de Toulouse-Oncopôle, avenue Hubert Curien, 31100 Toulouse, France.*

### **Corresponding author**

Telephone: +01133 531156016; Fax: 01133 5 31 15 53 36.

Email: Dupret-Bories.Agnes@iuct-oncopole.fr

**Word count:** 3096 words

# **Physician Practice Variation in head and neck cancer therapy: results of a national survey**

## **INTRODUCTION**

Head and neck cancer (HNC) account for about 4% of cancers in developed countries. Worldwide, HNC accounts for more than 650,000 cases and 330,000 deaths annually [1]. In 2020, in Europe, 104,500 people (74% men) will develop HNC and that will cause 43,300 deaths [2].

There are significant racial and socioeconomic disparities among HNC patients [3–5]. Affected patients tend to be older than before, have co-morbidities and less social support [6]. The influence of social factors on the incidence of these cancers has been highlighted, the risk of developing oral cancer being almost twice as high in the lower socio-economic classes and in patients with a low level of education [7]. In France, the risk of having HNC is higher in disadvantaged populations (1.89 and 1.56 times higher respectively for men and women) [8]. These social disparities have been found to impact survival rates [3,9]. In France, the 5-year survival differential between the most advantaged and least advantaged is 16% and 27% for men and women respectively [10].

The management of HNC is complex and often requires a combination of treatment, including surgery, radiotherapy, chemotherapy and/or targeted therapy [11,12]. Some tumor locations and stages have equivalent outcomes with medical (radiochemotherapy) and surgical treatment in terms of cure rates and functional impact. This is particularly the case for glottic cancers accessible to endoscopic surgery [13,14] or oropharynx cancers, in particular those induced by the human papilloma virus (HPV) [15,16]. Locally advanced tumors can be operated with often major functional impact (mutilating surgery) or treated by frontline radiochemotherapy with organ preservation intent [17]. In certain clinical situations, the choice between surgery and medical treatment leads to a totally different prognosis in terms of survival and locoregional control, i.e. recurrence in irradiated territory [18] or oral cavity cT4 cancer in elderly subjects [19,20].

In France, since 2003, the law has required each case to be discussed at a multidisciplinary consultation meeting, bringing together at least 3 doctors from different specialties dealing with head and neck cancer [21]. While medical decision making in HNC has been investigated by a single center qualitative study [22], no study has yet assessed the potential impact of the following: a) the practitioner's profession (surgeon or oncologist or radiotherapist); b) the patient's socio-professional context (gender, marital status and profession). However, the therapeutic choice may have an impact on survival and control of the disease, with the patient preferentially complying with the choice proposed by the practitioner [23–25].

We conducted a cross-sectional national study, investigating whether the practitioner's profession and certain characteristics of the patient, in particular profession, marital status and gender, could lead to heterogeneity in therapeutic decisions despite identical co-morbidities and tumors.

## **MATERIALS AND METHODS**

We conducted a cross-sectional, national study among otorhinolaryngologist (ENT) surgeons, maxillo-facial surgeons, medical oncologists and radiotherapists, who treat patients with HNC, in France.

Using an anonymized online questionnaire, on the SPHINX platform, data have been collected.

Practitioners were invited to respond via a link sent to their professional or personal mailboxes. The e-mail addresses were collected thanks to the collaboration of Head and Neck Intergroups, the practitioners having previously agreed to participate in the project.

Data collection took place from 14/12/2018 to 31/03/2019. The study was registered at [clinicaltrials.gov](https://clinicaltrials.gov) with the identifier NCT03663985.

The online questionnaire had two main sections. The first provided an assessment of the practitioner's characteristics, and the second consisted of seven clinical cases evaluating the practitioner's professional practice.

## Questionnaire evaluating professional practice:

This questionnaire section consisted of seven clinical cases from cases actually treated:

- Clinical case 1: 52-year-old patient, in good general condition, with cT2N1M0 oral cavity squamous cell carcinoma. This was a consensual scientific scenario, which made it possible to verify that the guidelines were respected. The case was used as an internal quality control, a non-surgical response to this item resulting in the exclusion of the practitioner from further study. This case was not used for analysis in the rest of the study.
- Clinical case 2: 88-year-old patient with locally advanced but resectable oral cavity squamous cell carcinoma cT4aN2bM0.
- Clinical case 3: 64-year-old patient with base of tongue squamous cell carcinoma contact with the midline cT4aN3bM0.
- Clinical case 4: 47-year-old patient with laryngeal squamous cell carcinoma accessible to partial laryngectomy cT1bN0M0.
- Clinical case 5: 59-year-old patient with hypopharyngeal squamous cell carcinoma, in contact with the vertebral plane cT3N2bM0.
- Clinical case 6: 82-year-old patient with oropharyngeal squamous cell carcinoma HPV+ cT2N1M0.
- Clinical case 7: 75-year-old patient with oropharyngeal squamous cell carcinoma HPV- cT2N0M0, context of recurrence in irradiated territory, i.e. history of supraglottic squamous cell carcinoma treated by surgery and radiotherapy (R).

A total of 36 scientific scenarios were created by crossing the six previous clinical cases (scientific scenarios 2 to 7) with six patient profiles with a variable social context, defined by a "profession/sex/marital status" set: single male manager, married male manager, single male blue-collar worker, married male blue-collar worker, female manager, married woman.

Each clinical case / socio-professional context (SPC) association was performed with a Latin Square design, ensuring that all factors were presented in a balanced and random fashion to all participants.

In the first phase, the online questionnaire including the scientific scenarios was evaluated within the promoting center and by two ENT surgeons from two other centers that had agreed to participate in the project, in order to check its feasibility before it was sent out to all participants.

The scientific scenarios were then grouped into three categories according to the prognostic and functional impact of the choice between surgical or medical treatment i.e. radio (chemo) therapy:

- Scientific scenarios 4 and 6: Surgical or medical treatment is possible without any difference in terms of locoregional control and survival, regardless of the treatment chosen, according to the data in the literature, with the two treatments carrying similar functional prognosis [14,26].
- Scientific scenarios 3 and 5: Surgical or medical treatment is possible without any difference in terms of locoregional control and survival regardless of the treatment chosen according to the data in the literature [27,28]. However, the proposed surgery is mutilating, i.e. total glossectomy (scientific scenario 3) and total pharyngolaryngectomy (scientific scenario 5).
- Scientific scenarios 2 and 7: For scientific scenario 2, the actual curative treatment modality is surgery followed by radiation. Chemotherapy or definitive radiotherapy are associated with significant reduced disease control in view of the age of the patient and the stage of the tumor (3 years disease free survival around 69% with surgery and adjuvant radiotherapy, and 21% with radical radiotherapy) [19,20,29]. Concerning scientific scenario 7, a case of relapse squamous cell carcinoma in an irradiated field, the choice will be made between curative surgery, palliative chemotherapy or re-irradiation alone with a low cure rate [18] (survival rate of 39% can be expected at 5 years after salvage surgery and 15.2% at 2 years for re-irradiation).

**Questionnaire on practitioners' personal and professional characteristics:**

The data collected concerned age, sex, specialty, type of institution, position held in the organization, number of patients treated per year.

### **Statistical analysis**

We investigated whether the social profile of patients influenced the choice of treatment based on a logistic model taking into account the interactions between the social profile of patients, their clinical profile, and the specialty of physicians. The model was fitted to the physicians' characteristics in terms of age, gender, position, annual activity and type of center. We were thus able to assess whether the social profile of patients influenced the choice of treatment, and if so, whether this choice depended on the physician's clinical profile and/or specialty. We used the contrasts between the marginal probabilities provided by the multivariate model, which we present in graphical form, as follows:

1: the difference between the probability of choosing surgery for each of the clinical case groups, among all practitioners (Figure 2);

2: the difference between the probability of choosing surgery for each of the SPC and the probability of choosing surgery for "a married male blue-collar worker", differentiating between the choices of surgeons (figure 3A) and those of medical oncologists or radiotherapists (figure 3B);

3: the difference between the probability of choosing surgery for each of SPC and the probability of choosing surgery for "a married male blue-collar worker" in each clinical case group, differentiating between the choices of surgeons (Figure 4A) and those of medical oncologists or radiotherapists (Figure 4B).

The absence of statistically significant inter-physician variability led us to select fixed-effect logistic models for our models. Statistical significance was evaluated at the 5% threshold. The analyses were performed with STATA release 14 software (StataCorp LP, College Station, TX).

## **RESULTS**

Of the 624 e-mails sent, we obtained 206 completed questionnaires and 202 questionnaires were usable for inclusion. Four participants were excluded, three because of missing data (sex and specialty), and one which was excluded due to his answer (other than surgery) to scientific scenario 1.

After survey administration, 247 e-mails were deemed ineligible for inclusion because 164 physicians were not in practice or did not perform head and neck oncology and 83 e-mails were not delivered.

Adjusted overall response rate calculated according to the American Association of Public Opinion Reporting (AAPOR) guidelines was 54.6%.

### **Characteristics of respondents**

Most respondents were men (64.9%), under 60 years of age (93.1%), surgeons (65.8%), working in university hospitals and cancer centers (72,8%). Their activity exceeded 100 patients treated per year in 39.6% of cases (Table 1).

### **Professional practice**

Concerning the responses to clinical cases, we obtained a total of 1212 observations from the 202 individuals included in the study who responded to the 6 scientific scenarios. Among these 1212 responses, 1208 were usable, as 4 responses had missing data, so they were therefore excluded from the analysis.

The impact of the practitioner's specialty on therapeutic decision-making is shown in Figure 1A. Surgeons proposed surgery in 49% of cases, whereas medical oncologists and radiotherapists opted for it in 34% of cases only (cf. Figure 1A). These differences were significant (20 percentage points) for scientific scenarios 2,4,6 and 7.

The impact of the patient's SPC on therapeutic decision-making is shown in Figure 1B. Married male blue-collar workers had the lowest probability of being offered surgery by surgeons (42%). Medical oncologists and radiotherapists made the same percentage of surgery proposals (42%) but were higher than all other categories.

Results of the multivariate model results (Figure 2) showed that differences in therapeutic decision-making between medical specialties varied according to the patient's clinical profile. Significant differences in the likelihood to offer surgery were observed for scientific scenarios 2, 4, 6 and 7, with surgery always being proposed more frequently by surgeons.

Figure 3 showed differences in the likelihood to offer surgery according to the SPC of patients. For surgeons, the "single male manager" was significantly more likely to be offered surgery than the "married male blue-collar worker". The differences were not significant for the other SPC (figure 3A). Among oncologists, the differences between SPC were less marked and not significant, but the single male blue-collar worker had the lowest probability of being offered surgery (figure 3B).

Finally, figure 4 showed differences in therapeutic management, according to social profile for each scientific scenario.

Medical oncologists and radiotherapists (figure 4B), more often offered surgery to the "single male manager" than to the "male married blue collar worker", for scientific scenarios 3 and 5. No significant difference in the likelihood to offer surgery was observed between medical oncologists and radiologists based on the patients' SPC for the other scientific scenarios.

For surgeons (figure 4A), there was a lower tendency to propose surgery to the "single male blue-collar worker" than to the reference category "married male blue-collar worker", for scientific scenarios 3 and 5. However, no significant difference in the likelihood to offer surgery was observed among surgeons.



## DISCUSSION

Head and neck cancer rank fourth overall in terms of incidence and fifth in terms of cancer mortality [30]. Improving the quality of care in HNC requires better multidisciplinary management in the elderly, who often suffer from co-morbidities and social isolation.

The purposes of clinical practice guidelines (CPG) are to improve the quality of patient care and health care outcomes [31]. Treatment decisions may be different for specific situations such as the elderly, where the difference between patient's real age and physiological age raises debates on the proposed treatment [32,33]. In the same way, cases of locally advanced cancers may receive different treatment depending on the center [34,35]. Differences can even be found according to which guideline is used [36,37]. In order to improve the quality of patient care and health care outcomes, we aimed to assess factors influencing our decision making beyond the evaluation of the tumor and patient co-morbidities alone.

In this national study of practitioners, based on clinical vignettes from routine practice, we find practice variations, related to the practitioner's profession and to the patient's SPC (socio-professional context) defined by a “profession/sex/marital status” set.

Overall, medical oncologists and radiotherapists offer less surgical management than surgeons, but the difference in practice between surgeons and oncologists varies according to the clinical context. The discrepancy is marked in situations where the oncologic outcome of surgery and the medical approach are equivalent (scientific scenarios 4 and 6) and when surgery appears to be superior in terms of curative potential but burdened by a significant functional impact (scientific scenarios 2 and 7). These variations could be explained by differences in behavioral profiles between practitioners [38], i.e. differences in risk and uncertainty attitudes among surgeons, oncologists and radiotherapists as assessed by another part of the study (Cros et al, in process). For scientific scenarios 3 and 5 (preservation protocol vs. mutilating surgery) there is no significant difference in therapeutic choice

between specialists, illustrating that surgeons do not propose more surgery than oncologists and radiotherapists when the surgery is mutilating.

These findings underline the importance of multidisciplinary tumor board (MTB), which use has spread rapidly around the world, starting more than 20 years ago in the USA and spreading to most European countries. It currently represents one of the criteria considered by the Organisation of European Cancer Institutes (OECI) in the accreditation process of a Comprehensive Cancer Center [39]. However, the practice is less widespread in Asia [40,41]. In France the modus operandi is defined by the French National Cancer Institute recommendations that require the participation of 3 practitioners from 3 different specialties, including at least one surgeon from the specialty and one oncologist [21].

A study emphasized the crucial importance of these meetings by showing that 27% of patients had some change in tumor diagnosis, stage, or treatment plan following MTBs [42].

The strength of MTBs lies in the fact that they bring together multi-disciplinary competences. Although this issue has not yet been addressed in HNC cancer, Hussain and al. [43] found that collaboration between surgeons and oncologists could improve the survival of patients with stage III rectal cancer and reduce the overall cost of their management. In thoracic oncology, Hopmans et al. [44] showed that surgeons, oncologists and pneumologists were not influenced by the same criteria in their therapeutic choices, i.e. WHO-PS and co-morbidities for pneumologists vs. age and co-morbidities for oncologists and surgeons. Shapiro et al. [45] showed that disparities in the utilization of surgical resection for patients with resectable pancreatic cancer are associated with socioeconomic variables.

In the present study, the SPC of patients also influences the therapeutic choice according to the scientific scenario. When surgical or medical treatment is possible without any difference in terms of oncologic outcomes, but with mutilating surgery, the choice "mutilating surgery" was preferred in isolated patients with a lower SPC. We may postulate that such patient would be deemed less

observant to follow a close clinical follow-up after organ preservation therapy whose objective is an early detection of residual cancer authorizing salvage surgery.

This hypothesis was assessed in a qualitative study conducted by Loretto [22] looking at the social dimension of medical prescription in HNC. The author analyzed the debates of 355 MTB in a French university center to try to identify whether some therapeutic choices were made on the basis of non-clinical criteria. The SPC proved to be an important determinant of therapeutic choices. In this study, the patient accompanied by a next of kin could attend the discussion of his case. It allowed practitioners to gauge the patient's understanding of the disease and his involvement for example in the treatment or the weaning process [22]. This practice is spreading among various specialties but remains anecdotal in most of the teams. For example, in breast oncology, only 9% of the patients were invited to participate in a MTB. Among invited patients, only 49% of them actually participated in a MTB [46]. Patients' participation in these meetings is receiving mixed support from the medical teams. Indeed, less than a third of surgeons, medical, and radiation oncologists were supportive of involving women in the MTB. In contrast, the vast majority of breast cancer advocates and breast cancer nurses were supportive of this approach [47]. There is a social demand in France for more patient and healthcare user information as well as greater participation to the medical decision making process [48]. However some factors such as age, education and so SPC have been identified as influencing factors for decision comprehension [49].

Other authors have evaluated the impact of patients' SPC on treatment choices in different types of cancer. Thus, adult patients with acute leukemia, harboring low economic status, are less likely to be offered chemotherapy or bone marrow transplantation [50]. Patients with digestive, thoracic or breast cancer belonging to the lowest SPC category were also less likely to be offered maximal curative treatment [45,51–54]. However, in these retrospective studies, co-morbidities or social support received by the patient were not considered, which could have influenced the therapeutic choice.

Our model limited the presence of such biases. The use of scientific scenarios has already been validated for exploring variations in practice [55,56]. We used scientific scenarios with various clinical

profiles, distributed according to a Latin square design, to ensure the balanced independent distribution of social context and gender across the practitioners. We were thus able to directly test the influence of these parameters on the evaluation of the scientific scenarios by the practitioners and their therapeutic proposal.

In addition, several studies investigating the link between SPC and treatment decisions were performed by teams in North America, where SPC is defined by access to private insurance [57–60]. This represents a confounding bias, as uninsured patients are unlikely to choose to undergo expensive surgery. The French health system allows free access to care for all, particularly in oncology. In a retrospective cohort study conducted in Canada, where medical care is freely available, the most disadvantaged women with breast cancer were less likely to receive maximalist treatment [61]. Therefore, despite equal access to care for the entire population, differences in therapeutic care persist between patients from different social classes.

Regarding the influence of patients' gender, surgeons in our study, tended to offer more surgical management to women regardless of their clinical profile (figure 4A), with an inverse relationship among oncologists and radiotherapists (Figure 4B). Gender disparity in HNC treatment has recently received attention. Katzel et al in 2019 [62,63] found a significant difference in survival between women and men in HNC that was directly related to lower intensity treatment in women, i.e. women received less intensive chemotherapy and radiotherapy. Further analysis is needed to fully understand why some patients benefit from more aggressive measures than others. One of the factors to be studied is perhaps the therapist himself, as suggested by the present findings.

One of the main limitations of our study is the decision to interview practitioners on an individual basis, whereas each case being discussed in MTB [21] in order to reduce inter-individual variability [64,65]. A review of the literature on MTB shows that although most decisions are based on existing recommendations, 30% of them are made outside of any guidelines [66,67]. This complexity was illustrated by highlighting clinical cases inviting discussion. However, not all participants had the same influence during these meetings. Castel et al [66] found that in 50 out of 219 discussions on

sarcoma management, the therapeutic decision was influenced by the information provided by the referring doctor about the patient's physical or psychological condition.

It is important to detect all factors that may potentially influence survival and functional outcomes in patients with HNC. This study could serve as a starting point to show that disparities in clinical practice may depend on the specialty of the healthcare professional and on the patient's SPC and marital status. We now intend to compare individual treatment choices to choices made at the end of MTB in order to establish whether our findings concerning treatment decisions and SPC persist.

## **CONCLUSION:**

To our knowledge, this is the first study showing that in HNC, a specialty where social inequalities are marked, therapeutic decisions are influenced by patients' socio-economic status, their gender and the clinician's specialty, even though they may have identical tumor and identical co-morbidities. All possible efforts to improve the quality of care for these patients should be put in place, and the use of data on the SPC and the patient's marital status when making therapeutic choices should be discussed.

Collaboration between surgeons, oncologists and radiotherapists should be strengthened with a view to harmonizing the decision-making process.

**Funding:** This research was funded by the Groupement Inter-Régional de Recherche Clinique et d'Innovation du Sud-Ouest (GIRCI SOHO).

## **Acknowledgement:**

This research was funded by the Groupement Inter-Régional de Recherche Clinique et d'Innovation Sud-Ouest (GIRCI SOHO).

GETTEC/GORTEC/GERCOR/SFORL/SFCCF/UNICANCER intergroup

Pr Emmanuel Babin, Dr Dominique De Raucourt, Dr Michel Rives and Dr Christian Borel who have evaluated the online questionnaire including the scientific scenarios.

## REFERENCES:

1. American Cancer Society. <https://cancerstatisticscenter.cancer.org/>.
2. European Cancer Information System. <https://ecis.jrc.ec.europa.eu/>.
3. Gaubatz ME, Bukatko AR, Simpson MC, Polednik KM, Adjei Boakye E, Varvares MA, et al. Racial and socioeconomic disparities associated with 90-day mortality among patients with head and neck cancer in the United States. *Oral Oncol.* 2019;89:95–101.
4. Panth N, Barnes J, Sethi RKV, Varvares MA, Osazuwa-Peters N. Socioeconomic and Demographic Variation in Insurance Coverage Among Patients With Head and Neck Cancer After the Affordable Care Act. *JAMA Otolaryngol Head Neck Surg.* 2019 31;
5. Massa ST, Osazuwa-Peters N, Adjei Boakye E, Walker RJ, Ward GM. Comparison of the Financial Burden of Survivors of Head and Neck Cancer With Other Cancer Survivors. *JAMA Otolaryngol Head Neck Surg.* 2019 Mar 1;145(3):239–49.
6. Trama A, Botta L, Foschi R, Visser O, Borrás JM, Žagar T, et al. Quality of Care Indicators for Head and Neck Cancers: The Experience of the European Project RARECAREnet. *Front Oncol.* 2019 Aug 28;9:837.
7. Conway DI, Petticrew M, Marlborough H, Berthiller J, Hashibe M, Macpherson LMD. Socioeconomic inequalities and oral cancer risk: A systematic review and meta-analysis of case-control studies. *Int J Cancer.* 2008 Jun 15;122(12):2811–9.
8. Bryere J, De Jardin O, Launay L, Colonna M, Grosclaude P, Launoy G, et al. Socioeconomic status and site-specific cancer incidence, a Bayesian approach in a French Cancer Registries Network study. *Eur J Cancer Prev.* 2018;27(4):391–8.
9. Reames BN, Birkmeyer NJO, Dimick JB, Ghaferi AA. Socioeconomic disparities in mortality after cancer surgery: failure to rescue. *JAMA Surg.* 2014 May;149(5):475–81.
10. Bryere J, Tron L, Menvielle G, Launoy G, French Network of Cancer Registries (FRANCIM). The respective parts of incidence and lethality in socioeconomic differences in cancer mortality. An analysis of the French network Cancer registries (FRANCIM) data. *Int J Equity Health.* 2019 03;18(1):189.
11. Pivot X, Felip E. Squamous cell carcinoma of the head and neck: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. *Annals of Oncology.* 2008 May;19:ii79–80.
12. Chow LQM. Head and Neck Cancer. Longo DL, editor. *N Engl J Med.* 2020 Jan 2;382(1):60–72.
13. Warner L, Chudasama J, Kelly CG, Loughran S, McKenzie K, Wight R, et al. Radiotherapy versus open surgery versus endolaryngeal surgery (with or without laser) for early laryngeal squamous cell cancer. *Cochrane Database Syst Rev.* 2014 Dec 12;(12):CD002027.

14. Bron LP, Soldati D, Zouhair A, Ozsahin M, Brossard E, Monnier P, et al. Treatment of early stage squamous-cell carcinoma of the glottic larynx: Endoscopic surgery or cricohyoidoepiglottopexy versus radiotherapy. *Head Neck*. 2001 Oct;23(10):823–9.
15. Howard J, Masterson L, Dwivedi RC, Riffat F, Benson R, Jefferies S, et al. Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small-volume primary oropharyngeal carcinoma. *Cochrane Database Syst Rev*. 2016 11;12:CD010963.
16. Ford SE, Brandwein-Gensler M, Carroll WR, Rosenthal EL, Magnuson JS. Transoral Robotic versus Open Surgical Approaches to Oropharyngeal Squamous Cell Carcinoma by Human Papillomavirus Status. *Otolaryngol Head Neck Surg*. 2014 Oct;151(4):606–11.
17. Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, et al. Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer. *JCO*. 2013 Mar 1;31(7):845–52.
18. Strojan P, Corry J, Eisbruch A, Vermorcken JB, Mendenhall WM, Lee AWM, et al. Recurrent and second primary squamous cell carcinoma of the head and neck: When and how to reirradiate: Reirradiation in Head and Neck Cancer. Eisele DW, editor. *Head Neck*. 2015 Jan;37(1):134–50.
19. Cannon RB, Sowder JC, Buchmann LO, Hunt JP, Hitchcock YJ, Lloyd S, et al. Increasing use of nonsurgical therapy in advanced-stage oral cavity cancer: A population-based study: Utilization and treatment outcomes in advanced-stage oral cavity cancer. *Head Neck*. 2017 Jan;39(1):82–91.
20. Chinn SB, Myers JN. Oral Cavity Carcinoma: Current Management, Controversies, and Future Directions. *JCO*. 2015 Oct 10;33(29):3269–76.
21. Plan cancer 2003-2007. Ministère de la santé, de la famille et des personnes handicapées; 2003.
22. Loretta A. The social logics of medical decision-making. A study of prescription criteria in head and neck cancer. *Sciences sociales et santé*. 2019 Dec 1;37(4):37–62.
23. Henman MJ, Butow PN, brown RF, Boyle F, Tattersall MHN. Lay constructions of decision-making in cancer. *Psycho-Oncology*. 2002 Jul;11(4):295–306.
24. Minami CA, King TA, Mittendorf EA. Patient preferences for locoregional therapy in early-stage breast cancer. *Breast Cancer Res Treat*. 2020 Jul 20;
25. Alimohamad H, Yilmaz D, Hamming JF, Schepers A. Identifying Factors Influencing Decision Making in Patients Diagnosed with Carotid Body Tumors: An Exploratory Study. *Annals of Vascular Surgery*. 2020 Jun;S0890509620304519.
26. Kelly JR, Park HS, An Y, Yarbrough WG, Contessa JN, Decker R, et al. Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancer. *Oral Oncology*. 2018 Apr;79:64–70.

27. Yoshimoto S, Kawabata K, Mitani H, Yonekawa H, Beppu T, Fukushima H, et al. Treatment results for 84 patients with base of tongue cancer. *Acta Oto-Laryngologica*. 2007 Jan;127(sup559):123–8.
28. Kim JW, Kim MS, Kim S-H, Kim JH, Lee CG, Kim GE, et al. Definitive Chemoradiotherapy Versus Surgery Followed by Adjuvant Radiotherapy in Resectable Stage III/IV Hypopharyngeal Cancer. *Cancer Res Treat*. 2016 Jan 15;48(1):45–53.
29. Murthy V, Agarwal J, Laskar Sg, Gupta T, Budrukkar A, Pai P, et al. Analysis of prognostic factors in 1180 patients with oral cavity primary cancer treated with definitive or adjuvant radiotherapy. *J Can Res Ther*. 2010;6(3):282.
30. Defossez G. Synthèse - Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018. INCA; 2019.
31. Pentheroudakis G, Stahel R, Hansen H, Pavlidis N. Heterogeneity in cancer guidelines: should we eradicate or tolerate? *Annals of Oncology*. 2008 Dec;19(12):2067–78.
32. Amini A, Jones BL, McDermott JD, Serracino HS, Jimeno A, Raben D, et al. Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base: CRT for HNSCC in the Elderly. *Cancer*. 2016 May 15;122(10):1533–43.
33. Haehl E, Rühle A, David H, Kalkreuth T, Sprave T, Stoian R, et al. Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly? *Radiat Oncol*. 2020 Feb 4;15(1):31.
34. Guttmann DM, Kobie J, Grover S, Lin A, Lukens JN, Mitra N, et al. National disparities in treatment package time for resected locally advanced head and neck cancer and impact on overall survival. *Head & Neck*. 2018 Jun;40(6):1147–55.
35. Haddad RI, Posner M, Hitt R, Cohen EEW, Schulten J, Lefebvre J-L, et al. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. *Ann Oncol*. 2018 May 1;29(5):1130–40.
36. Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network*. 2020 Jul;18(7):873–98.
37. Grégoire V, Lefebvre J-L, Licitra L, Felip E, EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2010 May;21 Suppl 5:v184-186.
38. Bories P, Lamy S, Simand C, Bertoli S, Delpierre C, Malak S, et al. Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey. *Haematologica*. 2018 Dec;103(12):2040–8.
39. Bergamini C, Locati L, Bossi P, Granata R, Alfieri S, Resteghini C, et al. Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer? *Oral Oncology*. 2016 Mar;54:54–7.



40. Lee VHF, Chan JYW, Vardhanabhuti V, Kwong DLW, Leung TW, Chan SY, et al. Advancing Care for Head and Neck Cancers in a Multidisciplinary Tumour Board in the East. *Clinical Oncology*. 2019 Aug;31(8):549–59.
41. Liu JC, Kaplon A, Blackman E, Miyamoto C, Savior D, Ragin C. The impact of the multidisciplinary tumor board on head and neck cancer outcomes. *The Laryngoscope*. 2020 Apr;130(4):946–50.
42. Wheless SA, McKinney KA, Zanation AM. A prospective study of the clinical impact of a multidisciplinary head and neck tumor board. *Otolaryngol Head Neck Surg*. 2010 Nov;143(5):650–4.
43. Hussain T, Chang H-Y, Veenstra CM, Pollack CE. Collaboration Between Surgeons and Medical Oncologists and Outcomes for Patients With Stage III Colon Cancer. *J Oncol Pract*. 2015 May;11(3):e388-397.
44. Hopmans W, Zwaan L, Senan S, van der Wulp I, Damman OC, Hartemink KJ, et al. Differences between pulmonologists, thoracic surgeons and radiation oncologists in deciding on the treatment of stage I non-small cell lung cancer: A binary choice experiment. *Radiotherapy and Oncology*. 2015 Jun;115(3):361–6.
45. Shapiro M, Chen Q, Huang Q, Boosalis VA, Yoon CH, Saund MS, et al. Associations of Socioeconomic Variables With Resection, Stage, and Survival in Patients With Early-Stage Pancreatic Cancer. *JAMA Surg*. 2016 Apr 1;151(4):338.
46. Diekmann A, Heuser C, Ernstmann N, Geiser F, Groß SE, Midding E, et al. How do breast cancer patients experience multidisciplinary tumor conferences? – A description from the patient perspective. *The Breast*. 2019 Apr;44:66–72.
47. Butow P, Harrison JD, Choy ET, Young JM, Spillane A, Evans A. Health professional and consumer views on involving breast cancer patients in the multidisciplinary discussion of their disease and treatment plan. *Cancer*. 2007 Nov 1;110(9):1937–44.
48. Moumjid N, Christine Durif-Bruckert, Denois-Régnier V, Roux P, Soum-Pouyalet F. Shared decision making in the physician-patient encounter in France: a general overview in 2011. *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen*. 2011 Jan;105(4):259–62.
49. Schwaegermann M-K, Schranz M, Moehler M, Labenz C, Moringlane A, Schmidt M, et al. Any progress in informed consenting for cancer treatment? Results from a cross sectional analysis at a comprehensive cancer center. *J Cancer Res Clin Oncol*. 2021 Jan 9;
50. Jabo B, Morgan JW, Martinez ME, Ghamsary M, Wieduwilt MJ. Sociodemographic disparities in chemotherapy and hematopoietic cell transplantation utilization among adult acute lymphoblastic and acute myeloid leukemia patients. Palaniyandi S, editor. *PLoS ONE*. 2017 Apr 6;12(4):e0174760.
51. Thobie A, Mulliri A, Dolet N, Eid Y, Bouvier V, Launoy G, et al. Socioeconomic status impacts survival and access to resection in pancreatic adenocarcinoma: A high-resolution population-based cancer registry study. *Surgical Oncology*. 2018 Dec;27(4):759–66.


52. Greenwald HP, Polissar NL, Borgatta EF, McCorkle R, Goodman G. Social factors, treatment, and survival in early-stage non-small cell lung cancer. *Am J Public Health*. 1998 Nov;88(11):1681–4.
53. Frisell A, Lagergren J, Halle M, de Boniface J. Socioeconomic status differs between breast cancer patients treated with mastectomy and breast conservation, and affects patient-reported preoperative information. *Breast Cancer Res Treat*. 2020 Feb;179(3):721–9.
54. Bouchardy C, Verkooijen HM, Fioretta G. Social class is an important and independent prognostic factor of breast cancer mortality. *Int J Cancer*. 2006 Sep 1;119(5):1145–51.
55. Peabody JW, Luck J, Glassman P, Dresselhaus TR, Lee M. Comparison of Vignettes, Standardized Patients, and Chart Abstraction: A Prospective Validation Study of 3 Methods for Measuring Quality. *JAMA*. 2000 Apr 5;283(13):1715.
56. Rice N, Robone S, Smith P. Analysis of the validity of the vignette approach to correct for heterogeneity in reporting health system responsiveness. *Eur J Health Econ*. 2011 Apr;12(2):141–62.
57. Healy MA, Pradarelli JC, Krell RW, Regenbogen SE, Suwanabol PA. Insurance Status and Hospital Payer Mix Are Linked With Variation in Metastatic Site Resection in Patients With Advanced Colorectal Cancers: *Diseases of the Colon & Rectum*. 2016 Nov;59(11):1047–54.
58. Churilla TM, Egleston B, Bleicher R, Dong Y, Meyer J, Anderson P. Disparities in the Local Management of Breast Cancer in the US according to Health Insurance Status. *Breast J*. 2017 Mar;23(2):169–76.
59. Burt LM, Shrieve DC, Tward JD. Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database. *Advances in Radiation Oncology*. 2018 Apr;3(2):170–80.
60. Coburn N, Fulton J, Pearlman DN, Law C, DiPaolo B, Cady B. Treatment Variation by Insurance Status for Breast Cancer Patients. *Breast Journal*. 2008 Mar;14(2):128–34.
61. Paszat LF, Mackillop WJ, Groome PA, Zhang-Salomons J, Schulze K, Holowaty E. Radiotherapy for breast cancer in Ontario: rate variation associated with region, age and income. *Clin Invest Med*. 1998 Jun;21(3):125–34.
62. Goodwin PM. Gender Disparity in Head & Neck Cancer Treatment, Outcomes. *Oncology Times*. 2018 Jul 20;34.
63. Park A, Alabaster A, Shen H, Mell LK, Katzel JA. Undertreatment of women with locoregionally advanced head and neck cancer. *Cancer*. 2019 01;125(17):3033–9.
64. Jalil R, Soukup T, Akhter W, Sevdalis N, Green JSA. Quality of leadership in multidisciplinary cancer tumor boards: development and evaluation of a leadership assessment instrument (ATLAS). *World J Urol*. 2018 Jul;36(7):1031–8.
65. Lamb B, Green JSA, Vincent C, Sevdalis N. Decision making in surgical oncology. *Surgical Oncology*. 2011 Sep;20(3):163–8.

66. Castel P, Blay J-Y, Meeus P, Sunyach M-P, Ranchère-Vince D, Thiesse P, et al. [Organization and impact of the multidisciplinary committee in oncology]. *Bull Cancer*. 2004 Oct;91(10):799–804.
67. Orgerie M-B, Duchange N, Pélicier N, Chapet S, Dorval E, Rosset P, et al. [Decision process in oncology: the importance of multidisciplinary meeting]. *Bull Cancer*. 2010 Feb;97(2):255–64.


**Figure 1: Response rate in favor of surgery, for oncologists and surgeons, according to:**

- A- Clinical case**
- B- Social profile**

**A**




**B**



**Table 1: Practitioners' description from analyzable questionnaires (N=202)**

		Surgeon (n=133)		Medical oncologist / Radiotherapist (n=69)		Total	
		N	%	N	%	N	%
<b>Sex</b>	Female	91	31.6	29	42.0	71	35.2
	Male	42	68.4	40	58.0	131	64.9
<b>Age</b>	25 to 39 years	60	45.1	34	49.3	94	46.5
	40 to 59 years	62	46.6	32	46.4	94	46.5
	60 years over	11	8.3	3	4.4	14	6.9
<b>Center</b>	Cancer center / University hospitals	95	71.4	52	75.4	147	72.8
	Hospital center	22	16.5	5	7.3	27	13.4
	Clinic	16	12.0	12	17.4	28	13.9
<b>Fonction</b>	University professor/ Hospital practitioner	95	71.4	47	68.1	142	70.3
	Assistant	20	15.0	10	14.5	30	14.9
	Private activity	18	13.5	12	17.4	30	14.9
<b>Number of patients with HNC cancer treated per year</b>	Incomplete	0	0.0	1	1.5	1	0.5
	Fewer than 10	4	3.0	0	0.0	4	2.0
	10 to 50	47	35.3	16	23.2	63	31.2
	51 to 100	30	22.6	24	34.8	54	26.7
	More than 100	52	39.1	28	40.6	80	39.6

**Figure 2: Difference in probability of choosing surgery, for each predefined clinical case association, among all specialists**





**Figure 3: Difference in probability of choosing surgery, for each social profile in comparison with the “married male blue-collar worker” for:**

**A- Surgeons**

**B- Medical oncologists and radiotherapists**

**A**




**B**

**Figure 4: Probability of choosing surgery, for different social profiles in comparison with "married male blue-collar worker" according to clinical cases for:**

**A- Surgeons**

**B- Medical oncologists and radiotherapists**

**A**





**B**

